MILAN, ITALY--(Marketwire - February 20, 2008) - Milan, February 20, 2008 - Recordati announced the approval of Zan-Extra®, a fixed combination of lercanidipine and enalapril indicated for the treatment of hypertension, in Australia. The Australian Register of Therapeutic Goods (ARTG) communicated its decision to approve the registration submitted by licensee Solvay Biosciences of Zan-Extra® in its two dosage forms containing lercanidipine 10mg/enalapril 10mg and lercanidipine 10mg/enalapril 20mg. The launch in Australia of this new product originated by Recordati is planned to take place in April.
